Project Grant DAMD170110827

This Project Grant award of $683,979.00, provided by the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), supports research at Weill Medical College of Cornell University to define the molecular mechanisms underlying distinct prostate cancer subtypes and their progression to treatment-resistant disease. The research aims to elucidate how early genetic alterations, particularly mutations in the SPOP gene, impact prostate cancer lineage fidelity and shape...

This federal Project Grant award, valued at $358,702.00, was provided by the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research) to The Research Foundation For The State University Of New York, doing business as Stony Brook University. The award supports research aimed at elucidating the mechanism linking oncogene-induced replication stress to DNA replication fork integrity, with a focus on the role of the Timeless (TIM) protein in modulating oncogene-induced...

This federal Project Grant award of $125,619.00 from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) supports research by the Stowers Institute for Medical Research to investigate the relationship between natural variations in human centromeric DNA sequences and chromosome segregation accuracy. The research team is utilizing cutting-edge genomic, cytogenetic, and high-resolution microscopy techniques to map centromeric sequences and associated kinetochore...

This Project Grant award of $371,719 from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) supports research by the University of Pennsylvania to characterize epigenetic targets in prostate cancer. The key objectives are to: Gain mechanistic insights into how the histone methyltransferase NSD2 influences the chromatin landscape to facilitate the assembly of the androgen receptor (AR) enhanceosome complex and enhance AR-driven transcription in prostate cancer...

This federal Project Grant award for $710,980.00 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research aimed at defining the molecular mechanisms and therapeutic potential of targeting the SPOP ubiquitin signaling pathway in prostate cancer. Key objectives include: Elucidating the role of the SPOP pathway regulator G3BP1 in driving prostate tumorigenesis and evaluating the ability to target this upstream axis. Establishing the...

The Dana-Farber Cancer Institute, Inc. was awarded a $720,252 Cooperative Agreement (U01CA296432) by the National Cancer Institute under the Cancer Cause and Prevention Research (CFDA 93.393) program. The project aims to characterize the genetic risk of cancer across diverse populations through multi-ancestry epigenome profiling and chromatin QTL discovery. Key objectives include identifying chromatin QTLs (cQTLs) that confer risk of prostate cancer in men of African ancestry, leveraging cQTLs...

This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $627,474 to the Dana-Farber Cancer Institute to conduct research aimed at leveraging innovative epigenomic methods and signatures to inform the understanding of prostate cancer lineage plasticity, including treatment-emergent neuroendocrine prostate cancer (NEPC). The key goals are to utilize epigenomic signatures to detect NEPC and predict enzalutamide resistance, as well...

This Project Grant award of $139,184 from the National Cancer Institute's (NCI) Cancer Research Manpower program (CFDA 93.398) supports research by the Fred Hutchinson Cancer Center in Seattle, Washington to investigate the role of RNA components of the translation apparatus in prostate cancer plasticity and therapy resistance. The research aims to elucidate how a specific tRNA, ARG-TCT-1-1, impacts lineage plasticity in prostate cancer, and determine the mechanisms by which 5' UTR-specific mRNA...

This Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), provides $607,250 to the Scripps Research Institute in La Jolla, CA to investigate the role of DNA polymerase theta (POLQ) in repairing replication-associated DNA double-strand breaks and exploiting this as a potential cancer treatment strategy. The award period runs from September 1, 2024 to August 31, 2029. The key objectives of this research project are to...

This $832,818 Project Grant, awarded on December 5, 2024 by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program, supports research by the University of Massachusetts Boston (UMass Boston) to investigate the role of the SETD7 enzyme in preventing prostate cancer progression and therapy resistance. The key objectives are to: 1) assess SETD7 protein expression and its correlation with LSD1, AR, and other epigenetic regulators in...